Intra-abdominal recurrence from colorectal carcinoma: Differences and similarities between local and peritoneal recurrence.


Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 28 11 2018
revised: 12 02 2019
accepted: 28 10 2019
pubmed: 11 11 2019
medline: 31 10 2020
entrez: 11 11 2019
Statut: ppublish

Résumé

Peritoneal recurrences from colo-rectal cancer can be isolated (PR) or associated with local recurrences (LR). The purpose of this study was to analyze patterns and outcomes of LR and PR. Analyze from a prospective database of 108 patients treated with CCS plus HIPEC at two cancer centers between 2008 and 2015. The population was divided into an LPR group (presence of LR with or without PR, n = 56) and a PR group (isolated PR, n = 52). The patients characteristics (age, sex, Charlson score, PCI) or perioperative treatments were comparable between the groups. The median number of resected organs for tumor involvement (respectively, 2 vs 1; p < 0.001), the percentage of patients with metastatic lymph nodes (LN+) from the resected specimen (respectively, 25% vs 7%; p = 0.016) and the mortality rate (respectively, 9% vs 0%; p = 0.023) were significantly higher in the LPR group. After a median follow-up of 32 (1-108) months, median overall survival was comparable between the two groups (respectively, 46 vs 42 months; p = 0.262). LR is associated with a higher incidence of organ invasion, LN involvement (25%) and postoperative mortality. Optimal surgical resection of LR with systematic lymphadenectomy of invaded organs seems mandatory.

Sections du résumé

BACKGROUND BACKGROUND
Peritoneal recurrences from colo-rectal cancer can be isolated (PR) or associated with local recurrences (LR). The purpose of this study was to analyze patterns and outcomes of LR and PR.
METHODS METHODS
Analyze from a prospective database of 108 patients treated with CCS plus HIPEC at two cancer centers between 2008 and 2015.
RESULTS RESULTS
The population was divided into an LPR group (presence of LR with or without PR, n = 56) and a PR group (isolated PR, n = 52). The patients characteristics (age, sex, Charlson score, PCI) or perioperative treatments were comparable between the groups. The median number of resected organs for tumor involvement (respectively, 2 vs 1; p < 0.001), the percentage of patients with metastatic lymph nodes (LN+) from the resected specimen (respectively, 25% vs 7%; p = 0.016) and the mortality rate (respectively, 9% vs 0%; p = 0.023) were significantly higher in the LPR group. After a median follow-up of 32 (1-108) months, median overall survival was comparable between the two groups (respectively, 46 vs 42 months; p = 0.262).
CONCLUSIONS CONCLUSIONS
LR is associated with a higher incidence of organ invasion, LN involvement (25%) and postoperative mortality. Optimal surgical resection of LR with systematic lymphadenectomy of invaded organs seems mandatory.

Identifiants

pubmed: 31707314
pii: S0960-7404(18)30472-9
doi: 10.1016/j.suronc.2019.10.018
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-29

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Frédéric Dumont (F)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France. Electronic address: frederic.dumont@ico.unicancer.fr.

Solène Joseph (S)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Gérard Lorimier (G)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Valéria De Franco (V)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Romuald Wernert (R)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Valérie Verriele (V)

Department of Pathology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Olivier Kerdraon (O)

Department of Pathology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Loic Campion (L)

Department of Statistics, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Olivier Capitain (O)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Véronique Guerin-Meyer (V)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Judith Raimbourg (J)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Hélène Senellart (H)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Sandrine Hiret (S)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Jean-Luc Raoul (JL)

Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Emilie Thibaudeau (E)

Department of Surgical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH